Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
03/2011
03/29/2011US7915275 polymorphic forms alpha , beta and gamma; for the oral or topical route; In case of invasive bacteria, it may be useful to use the most bioavailable polymorphic form, whereas in case of non-invasive pathogens it may be more appropriate to use the less adsorbed forms, since they are safer
03/29/2011US7915274 Nitrogen containing heterocyclic compounds and medicines containing the same
03/29/2011US7915273 Compositions and methods for inhibition of the JAK pathway
03/29/2011US7915272 1,4-diaza-bicyclo[3.2.2]nonyl pyrimidinyl derivative and its medical use
03/29/2011US7915271 1,3-oxazolidin-2-one derivatives useful as CETP inhibitors
03/29/2011US7915270 Oxazole ketones as modulators of fatty acid amide hydrolase
03/29/2011US7915269 treating gout with ritonavir; side effect reduction of colchicine
03/29/2011US7915268 And 8-substituted 2-(imidazolo[4,5-c]pyridinyl)purines; Janus kinase 3 inhibitors; autoimmune diseases, inflammatory disease, mast cell mediated disease and transplant rejection
03/29/2011US7915267 Heterocyclic amide compound and use thereof
03/29/2011US7915266 6-aryl-7-halo-imidazo[1,2-a]pyrimidines as anticancer agents
03/29/2011US7915265 Combinations for the treatment of immunoinflammatory disorders
03/29/2011US7915264 Drugs for treating pain formed by arylation
03/29/2011US7915263 Aminopyridine derivatives having aurora A selective inhibitory action
03/29/2011US7915262 Combination preparations comprising SLV308 and a dopamine agonist
03/29/2011US7915261 Pyridyl non-aromatic nitrogen-containing heterocyclic-1-carboxylate compound
03/29/2011US7915260 Urotensin II receptor antagonists
03/29/2011US7915259 7-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]phenyl}-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxylic acid cyclopropyl-(2,3-dimethylbenzyl)amide; retin inhibitor with other active ingredients; cardiovascular diseases and renal insufficiency
03/29/2011US7915258 Substituted 2,5-dihydro-3H-pyrazolo[4,3-C]pyridazin-3-one derivatives, preparation thereof and therapeutic use of the same
03/29/2011US7915257 Use of triazinetrione sulfones for combating coccidiosis
03/29/2011US7915256 Triazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases
03/29/2011US7915255 Metabolism-modulating agents and uses therefor
03/29/2011US7915254 Photosensitizers for photodynamic therapy; killing tissue, cells; anticancer agents
03/29/2011US7915253 4-[2,6-Dimethyl-4-(4-trifluoromethoxy-phenyl)-piperazine-1-sulfonyl]-indan-2-carboxylic acid; peroxisome proliferator activated receptors modulator; antidiabetic, antiinflammatory agent; obesity, hyperinsulinemia, metabolic syndrome X, polycystic ovary syndrome, ischemia-associated organ injury
03/29/2011US7915252 Sulfonyl compounds as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1
03/29/2011US7915251 Alpha-helix mimetics and methods relating to the treatment of fibrosis
03/29/2011US7915250 anticarcinogenic agent; 1-({4-[(2-fluoro-4-iodophenyl)amino]-3-thienyl}carbonyl)azetidin-3-amine
03/29/2011US7915249 serotonin 5-HT2A, 5-HT2C and dopamin D2 receptors antagonist, and norepinephrine reuptake inhibitor; antidepressant, anxiolytic agent; psychosis, schizophrenia, bipolar and sexual disorders, obesity
03/29/2011US7915248 Boronated metal-phthalocyanines, process for their preparation, pharmaceutical compositions comprising them and use thereof
03/29/2011US7915247 Methods of use of fenofibric acid
03/29/2011US7915246 Milnacipran; sub-class of dual serotonin norepinephrine reuptake inhibitors characterized by a non-tricyclic structure and inhibit the reuptake of norepinephrine to an equal or greater extent than they inhibit the reuptake of serotonin; with gabapentin, pregabalin; no phenylalanine, tyrosine, tryptophan
03/29/2011US7915245 Using small molecules as binding ligands, for the recruitment of Fas-associated death domain protein, activation of death-inducing signaling complex, caspase-8, and apoptosis in malignant cells; anticarcinogens, antitumor agents; enhanced cellular differentiation, minimizing cytolysis to healthy cells
03/29/2011US7915244 Methods for the treatment of a traumatic central nervous injury
03/29/2011US7915243 Topical skin care composition
03/29/2011US7915242 Vitamin D receptor antagonists and their use in treating asthma
03/29/2011US7915241 Preparation of 24 alkyl analogs of cholecalciferol and non-racemic compounds
03/29/2011US7915240 Immunomodulatory compounds and treatment of diseases related to an overproduction of inflammatory cytokines
03/29/2011US7915239 Treating lameness with an osseous and/or articular component which appear in a person or animal not suffering from fractures or arthritis; horses; veterinary medicine; bone disorders, osteoarthritis
03/29/2011US7915238 Immunomodulatory compounds and methods of use thereof
03/29/2011US7915237 Production of pure stereoisomers of tricyclo[5.2.1.02.6]-dec-9-yl-xanthogenate and medicaments therefrom
03/29/2011US7915236 Proteasome inhibitors and methods of using the same
03/29/2011US7915235 High affinity ligands bind to clostridium difficile toxin A
03/29/2011US7915234 Pharmaceutically active uridine esters
03/29/2011US7915233 Compositions and methods for treatment of mitochondrial diseases
03/29/2011US7915232 4′-substituted nucleoside derivatives as inhibitors of HCV RNA replication
03/29/2011US7915231 Antisense modulation of C-reactive protein expression
03/29/2011US7915229 Compositions containing piperacillin and tazobactam useful for injection
03/29/2011US7915228 Derivatives of asimadoline with covalently bonded acids
03/29/2011US7915227 Pharmaceutical formulations employing short-chain sphingolipids and their use
03/29/2011US7915226 Methods of suppressing microglial activation
03/29/2011US7915009 Modulating NF-kappa B by administering antigens or polynucleotide encoding antigens, antibody; treating cancer, tumor, Alzheimer's disease or a spongiform encephalopathy; DNA vaccine in kits
03/29/2011US7914831 Alpha acids, isoalpha acids, reduced isoalpha acids, tetra-hydroisoalpha acids, hexa-hydroisoalpha acids, beta acids from hops; nontoxic
03/29/2011US7914826 Method for promoting sleep
03/29/2011US7914823 Method and composition for the topical treatment of diabetic neuropathy
03/29/2011US7914819 Polysaccharide-based biomaterials
03/29/2011US7914818 Prevent drug abruse; side effect reduction; administering mixture of opioid antagonist, releasable form and sequestering agent
03/29/2011US7914817 Treatment of inflammatory bowel disease
03/29/2011US7914814 Adjust blood flow to scalp, penis
03/29/2011US7914811 Weight ratio of active drug agents with particle size >/= 50 mu m to shell being 1:5-1:15
03/29/2011US7914804 Slow release pharmaceutical preparation and method of administering same
03/29/2011US7914803 Ophthalmic compositions containing a synergistic combination of three polymers
03/29/2011US7914800 LTB4 as vaccine adjuvant
03/29/2011US7914793 Method for producing an antigenic substance and antibody
03/29/2011US7914778 Methods of treatment using IL-16 antagonist peptides
03/29/2011US7914776 Solid dispersions of opioid antagonists
03/29/2011US7914774 Skin care composition for accelerated production of collagen proteins and method of fabricating the same
03/29/2011US7914769 Compounds for treating human papillomavirus
03/29/2011US7914537 Devices and methods for the restoration of a spinal disc
03/29/2011CA2642324C Stable pharmaceutical composition of taxanes
03/29/2011CA2631880C Chromane substituted benzimidazoles and their use as acid pump inhibitors
03/29/2011CA2622798C 17.beta.-nitro-11.beta.-arylsteroids and their derivatives having agonist or antagonist hormonal properties
03/29/2011CA2620065C Methods and formulations for modulating lyn kinase activity and treating related disorders
03/29/2011CA2618857C 11-beta-hydroxysteroid dehydrogenase-1-inhibitor-diabetes-type 2-1
03/29/2011CA2610354C Substituted aryloxy-n-bicyclomethyl acetamide compounds as vr1 antagonists
03/29/2011CA2580843C Control of parasites in animals by the use of trifluoromethanesulfonanilide oxime ether derivatives
03/29/2011CA2573315C Benzoic acid derivatives as non-nucleoside reverse transcriptase inhibitors
03/29/2011CA2533545C Glycopeptide compositions
03/29/2011CA2498891C Thermolabile liposome with a controlled release temperature
03/29/2011CA2497237C N-substituted-2-oxodihydropyridine derivatives
03/29/2011CA2489276C Tricyclic steroid hormone nuclear receptor modulators
03/29/2011CA2483752C Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity
03/29/2011CA2472114C 2-o-(.beta.-d-glucopyranosyl) ascorbic acid, process for its production, and foods and cosmetics containing compositons comprising it
03/29/2011CA2470990C 2-indanylamino derivatives for the therapy of chronic pain
03/29/2011CA2469055C Aminotetralin derivatives as muscarinic receptor antagonists
03/29/2011CA2468715C Inhibitors of factor xa and other serine proteases involved in the coagulation cascade
03/29/2011CA2466671C Microspherules containing a pleuromutilin derivative
03/29/2011CA2465326C Pyrazolopyrimidines for decreasing ion flow through a voltage-dependent sodium channel
03/29/2011CA2463544C Cross-linked glycopeptide-cephalosporin antibiotics
03/29/2011CA2463521C Antisense modulation of insulin-like growth factor binding protein 5 expression
03/29/2011CA2462211C Naphthyridine derivatives, their preparation and their use as phosphodiesterase isoenzyme 4 (pde4) inhibitors
03/29/2011CA2460640C Diaryl ether derivatives, salts thereof and immunosuppressive agents using the same
03/29/2011CA2448083C Liquid preparations of fudosteine
03/29/2011CA2443672C Aryl and biaryl piperidines used as mch antagonists
03/29/2011CA2436980C Amido ether substituted imidazoquinolines
03/29/2011CA2436764C Rehydration composition
03/29/2011CA2435730C Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
03/29/2011CA2435146C Formulation of boronic acid compounds
03/29/2011CA2434616C (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions and uses thereof
03/29/2011CA2428223C Compounds and methods for promoting smoking cessation
03/29/2011CA2421974C Pulmonary delivery in treating disorders of the central nervous system
03/29/2011CA2420562C Creatine ester pronutrient compounds and formulations